Cargando…
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis
BACKGROUND: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. METHODS: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. RESULTS: In all patients,...
Autores principales: | Chamian, Francesca, Lin, Shao-Lee, Lee, Edmund, Kikuchi, Toyoko, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Cardinale, Irma, Khatcherian, Artemis, Novitskaya, Inna, Wittkowski, Knut M, Krueger, James G, Lowes, Michelle A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906741/ https://www.ncbi.nlm.nih.gov/pubmed/17555598 http://dx.doi.org/10.1186/1479-5876-5-27 |
Ejemplares similares
-
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
por: Zaba, Lisa C., et al.
Publicado: (2008) -
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
por: Zaba, Lisa C., et al.
Publicado: (2007) -
Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
por: Suárez-Fariñas, Mayte, et al.
Publicado: (2010) -
Post-Therapeutic Relapse of Psoriasis after CD11a Blockade Is Associated with T Cells and Inflammatory Myeloid DCs
por: Johnson-Huang, Leanne M., et al.
Publicado: (2012) -
The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
por: Jenneck, Claudia, et al.
Publicado: (2007)